Jacques Galipeau

Dr. Jacques Galipeau is a renowned academic health center biopharmaceutical leader with expertise ranging from bench discovery to clinical translation of biologics and cell therapeutics. His experience includes leading groups in discovery research, GMP compliant cell manufacture, clinical trial design, and FDA regulatory approval within academia. He excels in guiding programs from pre-clinical stages to first-in-human studies across various therapeutic areas, with a strong emphasis on team building and strategic decision-making.

As the Don and Marilyn Anderson Professor of Oncology at the University of Wisconsin in Madison, Dr. Galipeau is a practicing hematologist known for his work in mesenchymal stromal cell therapies. He is internationally recognized for his contributions to the development of engineered synthetic cytokines for immune disorders and cancer treatment. Additionally, he serves as the 2020 President-Elect of the International Society of Cell and Gene Therapy (ISCGT), demonstrating his leadership within the field.

Dr. Galipeau's educational background includes a Fellowship in Hematology & Medical Oncology from New England Medical Center (Tufts), a Residency in Internal Medicine from McGill University, an MD in Medicine from Université de Montréal, and a Fellowship in Gene Therapy from St. Jude Children's Research Hospital. His extensive academic and leadership roles have included serving as the Associate Dean for Therapeutics Development at the University of Wisconsin-Madison, Director of the UW Program for Advanced Cell Therapy (UW-PACT), and various positions at Emory University School of Medicine and McGill University.

Throughout his career, Dr. Galipeau has contributed significantly to the advancement of cell and gene therapy, pharmacovigilance, and health outcomes research. His expertise in translating basic university research into impactful healthcare solutions while ensuring regulatory compliance and quality assurance is evident in his diverse professional portfolio. His innovative approach to designing clinical trials and developing novel therapies underscores his commitment to improving patient care and advancing the field of biopharmaceuticals.

In summary, Dr. Jacques Galipeau is a distinguished academic figure and biopharmaceutical leader whose contributions to translational research, cell therapy, and innovative treatment modalities have made a lasting impact on the field of oncology and beyond.